Overview

Compare IBI305 and Bevacizumab on Pharmacokinetics/Safety/Immunogenicity on Healthy Male

Status:
Completed
Trial end date:
2017-08-17
Target enrollment:
Participant gender:
Summary
To confirm the PK similarity of IBI305 and bevacizumab in healthy volunteers .
Phase:
Phase 1
Details
Lead Sponsor:
Innovent Biologics (Suzhou) Co. Ltd.
Treatments:
Bevacizumab